Angiotensin receptor blockers and myocardial infarction.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

46 citing papers in PubMed, 6 syntheses or guidelines pooled it.

1. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.PLoS medicine · 2016
   Pooled it
2. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials.BMJ (Clinical research ed.) · 2011
   Pooled it
3. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.BMJ (Clinical research ed.) · 2009
   Pooled it
4. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension.Journal of human hypertension · 2006
   Pooled it
5. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.Heart (British Cardiac Society) · 2005
   Guideline
6. Angiotensin receptor blockers and risk of myocardial infarction: systematic review.BMJ (Clinical research ed.) · 2005
   Pooled it
7. [Cardioprotection by means of Candesartan in cardiac insufficiency. CHARM overall partial evaluation (Candesartan in heart failure assessment of reduction in mortality and morbidity)].Der Internist · 2006
   Trial
8. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.Diabetologia · 2005
   Trial
9. Antihypertensive therapy to prevent cardiac death: A study of combined ACE inhibitors and β-blockers-a retrospective cohort study in Tsunan Town, Japan.PloS one · 2025
   Observational
10. Exploring the Cardiovascular Protective Effects of Baicalin: A Pathway to New Therapeutic Insights.Current topics in medicinal chemistry · 2025
    Review
11. Angiotensin converting enzyme inhibitors versus angiotensin II type 1 receptor blockers in patients with acute myocardial infarction and prediabetes after successful implantation of newer-generation drug-eluting stents.Cardiology journal · 2023
    Article
12. Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics.Clinical science (London, England : 1979) · 2022
    Review
13. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers might be associated with lung adenocarcinoma risk: a nationwide population-based nested case-control study.American journal of translational research · 2020
    Article
14. Long-term clinical outcome between beta-blocker with ACEI or ARB in patients with NSTEMI who underwent PCI with drug-eluting stents.Journal of geriatric cardiology : JGC · 2019
    Article
15. Effects of Ivabradine on Left Ventricular Systolic Function and Cardiac Fibrosis in Rat Myocardial Ischemia-Reperfusion Model.Chonnam medical journal · 2018
    Article
16. Thymosin β4 promotes the survival and angiogenesis of transplanted endothelial progenitor cells in the infarcted myocardium.International journal of molecular medicine · 2017
    Article
17. Comparison of endothelial function improvement estimated with reactive hyperemia index between ramipril and telmisartan in hypertensive patients.Clinical hypertension · 2017
    Article
18. The Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Diabetes.Journal of clinical hypertension (Greenwich, Conn.) · 2016
    Observational
19. Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction.Heart and vessels · 2011
    Article
20. Role of RAAS Inhibition in the Prevention of Cardiovascular Disease.Current treatment options in cardiovascular medicine · 2011
    Article

Corrections and comments

• Commented on by
  Angiotensin receptor blockers and myocardial infarction: results reflect different cardiovascular states in patients with types 1 and 2 diabetes.2005
• Commented on by
  Angiotensin receptor blockers and myocardial infarction: analysis of evidence is incomplete and inaccurate.2005
• Commented on by
  Angiotensin receptor blockers and myocardial infarction: cautions voiced are biologically credible.2005
• Commented on by
  Angiotensin receptor blockers and myocardial infarction: direct comparative studies are needed.2005

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as